JMP Securities analyst Jason Butler reiterated a Buy rating on Precigen (NASDAQ:PGEN) on Tuesday, setting a price target of $13, which is approximately 145.75% above the present share price of $5.29.
Butler expects Precigen to post earnings per share (EPS) of -$0.10 for the third quarter of 2021.
The current consensus among 2 TipRanks analysts is for a Moderate Buy rating of shares in Precigen, with an average price target of $11.5.
The analysts price targets range from a high of $13 to a low of $10.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $33.58 million and a net profit of -$15.13 million. The company's market cap is $1.09 billion.
According to TipRanks.com, JMP Securities analyst Jason Butler is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 6.6% and a 44.53% success rate.
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It focuses on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals. The product pipeline includes Isobutanol, Isobutyraldehyde, Farnesene, and Isoprene. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.